Skip to main content
Esc

Type to search

Articles / venture-startup-funding / CySEC removes Conotoxia, TTCM and OBR from compensation fund

CySEC removes Conotoxia, TTCM and OBR from compensation fund

Jun 20, 2026 · Source: leaprate.com · Topic:  venture-startup-funding · fintech

§ 01 Executive Snapshot

  • What: CySEC has removed Conotoxia, TTCM, and OBR from the Investor Compensation Fund.
  • Who: Cyprus Securities and Exchange Commission (CySEC), Conotoxia Ltd, TTCM Traders Trust Capital Markets Ltd, OBR Investments Ltd.
  • Why it matters: This action reflects ongoing regulatory adjustments in the Cypriot financial market, highlighting the challenges firms face in meeting licensing criteria.

§ 02 Key Developments

  • The Investor Compensation Fund withdrew the membership of Conotoxia Ltd, TTCM Traders Trust Capital Markets Ltd, and OBR Investments Ltd on 17 June.
  • Conotoxia lost its authorization on 5 June after CySEC concluded it no longer met licensing conditions, citing issues with board member suitability and organizational deficiencies.
  • TTCM and OBR voluntarily renounced their licenses, with TTCM's decision made on 14 May and OBR's in February, both without any breach findings.

§ 03 Strategic Context

  • This event fits into a broader trend of regulatory scrutiny and adjustments within the Cypriot financial services sector, particularly concerning the conduct and governance of CIFs.
  • The pattern of voluntary departures indicates a shift in the market landscape, potentially reshaping competitive dynamics among licensed firms in Cyprus.

§ 04 Strategic Implications

  • The immediate consequence is a reduction in the number of active firms in the market, which could lead to increased competition among the remaining players.
  • Long-term implications may include a more stringent regulatory environment, prompting firms to enhance compliance and governance standards to retain licenses.

§ 05 Risks & Constraints

  • Potential regulatory risks remain as CySEC continues to evaluate CIFs, which could lead to further removals or sanctions against firms that fail to comply with licensing requirements.
  • Competition may intensify as fewer firms operate under the CIF framework, possibly impacting market stability and client options.

§ 06 Watchlist / Forward Signals

  • Future developments to watch include any additional removals from the Investor Compensation Fund or further regulatory actions by CySEC.
  • The response of other CIFs to this regulatory shift may signal their compliance strategies and operational adjustments moving forward.
§ 07

Frequently Asked Questions

What happened to Conotoxia, TTCM, and OBR?

CySEC has removed Conotoxia, TTCM, and OBR from the Investor Compensation Fund due to various regulatory issues.

Why did CySEC remove these firms from the compensation fund?

The removal reflects ongoing regulatory adjustments, with Conotoxia losing authorization for not meeting licensing conditions, while TTCM and OBR voluntarily renounced their licenses.

When did these removals take place?

The Investor Compensation Fund withdrew the membership of these firms on 17 June, with Conotoxia losing its authorization on 5 June.

How might this impact the Cypriot financial market?

The removal of these firms could lead to increased competition among the remaining players and may prompt a more stringent regulatory environment.

§ 08

Related Articles